Although, there are only a handful of studies that report the phenotypic and functional significance of CD8+ T-cells in MS patients, one prominent feature that emerges from these studies is an underlying defect in the CD8+ Treg component. This evidence concerns the gene CD8A and myeloid sarcoma.